



National Institute of Diabetes and
Digestive and Kidney Diseases
Bethesda, Maryland 20892

August 23, 2007

Jerry L. Nadler, M.D.
Chief Science Officer
DiaKine Therapeutics, Inc.
1414 Sachem Place, Suite 3
Charlottesville, VA 22911

Dear Dr. Nadler:

Thank you for your recent response to the T1D-Preclinical Testing Program (T1D-PTP): <http://www.t1diabetes.nih.gov/T1D-PTP/>) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)- Request for Information: NOT-DK-07-009. Your request, "DT 22669: A New Agent for the Prevention and Reversal of Type 1 Diabetes—Request for Preclinical Efficacy Testing in the BB-DP Rat", received on May 1, 2007, was reviewed by a panel of experts convened by the NIDDK. The reviewers saw high scientific merit and novelty. NIDDK will be able to assist your project as specified in the request for information. The comments from the reviewers are included in this package.

We will be the contacts for defining the milestones and progress of your project. We anticipate your meeting with NIDDK and the contractor's staff, either in person or via teleconference, to facilitate this process in the near future. Thank you for your interest in the T1D-Preclinical Testing Program, and do not hesitate to contact us with any questions you may have.

Sincerely,

Guillermo Arreaza-Rubín, M.D.
Division of Diabetes, Endocrinology, and
Metabolic Diseases
National Institute of Diabetes and Digestive
and Kidney Diseases
6707 Democracy Blvd. Rm. 6101
Bethesda, MD 20892-5460
Telephone: (301) 594-4724
FAX: (301) 480-2688
E-mail: arreazag@niddk.nih.gov

Lisa Spain, Ph.D.
Division of Diabetes, Endocrinology, and
Metabolic Diseases
National Institute of Diabetes and Digestive
and Kidney Diseases
6707 Democracy Blvd. Rm. 695
Bethesda, MD 20892-5460
Telephone: (301) 451-9871
FAX: (301) 480-2688
E-mail: spainl@niddk.nih.gov